SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update

New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and

APMD

Related stories